Abstract A030: Lossless altered histone modification analysis system to investigate patient derived cancer organoids and circulating tumor cells from patients with prostate cancer
Zachary J. Kauffman(University of Wisconsin–Madison), Joshua M. Lang(University of Wisconsin–Madison), Kyle T. Helzer(University of Wisconsin–Madison), Kevin Koesser(University of Wisconsin–Madison), Erika Héninger(University of Wisconsin Carbone Cancer Center), Emma E. Recchia(University of Wisconsin–Madison), Jamie M. Sperger(University of Wisconsin–Madison), David Kosoff(University of Wisconsin–Madison), Shuang G. Zhao(University of Wisconsin–Madison), David J. Beebe(University of Wisconsin–Madison), Marina N. Sharifi(University of Wisconsin–Madison), David F. Jarrard(University of Wisconsin System)
Cited by 0
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Therapy-Induced Senescence in Cancer
|JNCI Journal of the National Cancer Institute|2010|822
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
|Proceedings of the National Academy of Sciences|2003|650